What question did this study set out to answer?

To evaluate the effect of MCC950, an NLRP3 inflammasome inhibitor, on functional recovery in aging mice after a stroke.

February 2, 2026

Abstract WP282: Neurofunctional improvement by MCC950 treatment in aging mice with stroke.

Key Points

To evaluate the effect of MCC950, an NLRP3 inflammasome inhibitor, on functional recovery in aging mice after a stroke.
30 aging mice randomized to MCC950 or placebo treatment after middle cerebral artery occlusion.
MCC950 administered at 10 mg IP daily for 30 days through a standardized protocol.
Functional assessments included neurological deficit score, corner test, beam walking, and others at 30 days post-stroke.
MCC950 treatment resulted in a significant improvement in Bederson Neuroscore (p=0.0336).
Improvements were noted in balance and coordination tests, including beam walk (p=0.045) and hanging wire tests (p=0.0015).
A significant increase in exploration was observed on the Y maze (p=0.0384), though no cognitive improvement was found in the novel object recognition test.

Abstract

Background: The inflammatory cascade worsens tissue injury and clinical outcomes in acute stroke. The NLRP3 inflammasome plays a central role in the innate immune system. Aged humans and aged mice exhibit chronic sterile inflammation, known as “inflammaging,” with chronic activation of the innate immune system. Our central hypothesis is that the inhibition of the NLRP3 inflammasome will improve long-term functional outcome in aged mice subjected to middle cerebral artery occlusion. Methods: We randomized 30 aging mice to MCC950, a specific inhibitor of NLRP3, 10 mg IP daily (N=15) or placebo (NS IP) (N=15) within 4 hours of stroke then daily for 30 days. We measured the Neurological deficit score, corner test, balance beam walking, novel object recognition, neuro battery test and Y maze at day 30 post stroke Results: Mice treated with MCC950 showed significant improvement in Bederson Neuroscore (p=0.0336; CI: -1.492 to -0.008) t at 48h. In the corner test on Day 30 there were significant changes (p=0.0414; CI: -4.893 to -0.1074) in right preferences, but nonsignificant changes (p=0.215) were observed on day 7. Similarly, we found significant improvement in beam walk (P=0.045; CI: -7.385 to -0.083) and hanging wire (p=0.0015; CI: 22.79 to 79.15) tests in MCC950 treated mice compared to vehicle treated mice treated stroke mice. Interestingly, MCC950 treatment significantly improved the Neuroscore (p=0.047; CI: -1.492 to -0.008) and Neuroscore battery score (p=0.0363; CI: -4.178 to -0.155) at d30. A Y maze test showed a significant number (p=0.0384; CI: 0.2387 to 7.928) of arms entries indicates improved exploration and locomotor activity in MCC950 treated mice. However, in cognitive test NOR test, we could not find significant improvement by MCC950 treatment. Conclusions: Inhibition of the NLRP3 inflammasome with MCC 950 is effective at improving long term functional outcome in aged mice. NLRP3 inhibitors are a promising treatment for acute stroke.

Read Full Paperexternally

Bookmark

View Full Paper

Cite This Study

Kamat et al. (Thu,) studied this question.

synapsesocial.com/papers/6980fbe1c1c9540dea80da2a https://doi.org/https://doi.org/10.1161/str.57.suppl_1.wp282

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Bookmark

View Full Paper